News
Vedolizumab supports intestinal stem cell recovery.
A recent study from the University of California, San Francisco showed that Vedolizumab (VDZ), an anti-integrin antibody, effective in the treatment for Colitis, plays an important role in limiting specific inflammatory immune, fibroblasts and endothelial cells to facilitate intestinal epithelial stem cell recovery. By using a combination of latest sequencing technologies, they provide a tool for comprehensive analysis of the inter cellular networks of the colon in health, disease, and during treatment. Implementing these new single-cell and spatial technologies simultaneously in individual patients will lead to more precise treatment algorithms, and therefore a way for precision medicine.
Click on the link below to see the study
https://www.nature.com/articles/s41467-024-45665-6?fromPaywallRec=false#Sec2
Gut bacteria break down cholesterol
In a new study, researchers found that gut bacteria can break down cholesterol. They identified bacteria in the human gut that have an enzyme that can convert cholesterol into a form that isn't absorbed by the body. The study supports previous work indicating a link between bacterial enzymes that can modify cholesterol. This research could potentially be used to develop probiotic-type treatments to replace or support traditional treatments for managing cholesterol, like statins.
For a summary of the research, click here
For the whole research paper, click here
Blog image credit: Susanna Hamilton, Broad Communications
